PARa-aOrtic LymphAdenectomy in Locally Advanced Cervical Cancer

ClinicalTrials.gov ID

NCT05581121

Lead Sponsor

Institut Claudius RegaudOTHER

Overall Status

Recruiting

Study Type

Interventional

Phase

Phase 3

Enrollment

510Estimated

Last Update Posted

Jul 7, 2026Actual

Start Date

Dec 20, 2023Actual

Primary Completion Date

Dec 20, 2033Estimated

Completion Date

Dec 20, 2033Estimated

Official Title

PARa-aOrtic LymphAdenectomy in Locally Advanced Cervical Cancer

Brief Summary

This is an international, multicenter and randomized open-label phase III study designed to demonstrate, in patients with stage IIIC1 cervical cancer, whether para-aortic lymphadenectomy followed by tailored chemoradiation is associated with increased disease-free survival compared to patients staged with FDG-PET/CT only followed by chemoradiation.

The planned sample size is 510; including 200 patients in France.

In this trial, patients will be assigned in one of the two following treatments arms:

• Arm A (control arm): Standard chemo-radiotherapy and brachytherapy according to EMBRACE II and ESGO/ESTRO recommendations.
• Arm B (experimental arm): Pretherapeutic para-aortic lymphadenectomy followed by tailored chemo-radiotherapy and brachytherapy.

Considering the changing standard treatment landscape of locally advanced cervical cancer, both arms (control arm and experimental arm) may also be treated according to the INTERLACE and KEYNOTE-A18 studies, if applicable, at the discretion of the attending physician.

Each patient will be followed up for 5 years.

A cost-utility study will be performed in patients included in France. Other countries could be involved in this specific study. It will assess the incremental cost-utility ratio (cost per QALY gained) of para-aortic lymphadenectomy followed by tailored chemo-radiation in patients with positive PALN compared to patients staged with PET/CT only followed by chemo-radiation.

This study also has ancillary objectives:

• Biologic: To study T cell exhaustion, immune changes during chemoradiation, HPV ctDNA dynamic evolution, and the par-aortic lymph node as a premetastatic niche.
• Radiomics: To study the contribution of radiomics and FDG-PET/CT metabolic parameters to predict para-aortic lymph node involvement and clinical outcome.
• Senti-PAROLA: To evaluate the accuracy (Sensitivity, specificity, positive and negative predictive value) of the para-aortic sentinel lymph node (SPA) for PALN staging, and to evaluate the prognostic value of low volume metastasis of SPA.

• Cervical Carcinoma
• Adenocarcinoma
• Adenosquamous Carcinoma

• Standard treatment: Control arm
• Experimental arm

Ages Eligible for Study

Adult (18-64)Older Adult (65+)

Sexes Eligible for Study

Female

Accepts Healthy Volunteers

No

Eligibility Criteria

Inclusion Criteria:

1. Age ≥ 18 years at time of study entry
2. Newly diagnosed histologically proven cervical squamous carcinoma, adenocarcinoma, or adenosquamous tumor
3. FIGO stage IIIC1 (FIGO 2018) cervical cancer with FDG-PET/CT showing FDG-positive pelvic nodes and FDG-negative PALN including equivocal lymph nodes in the common iliac and para-aortic regions. The highest positive lymph node must be located inferior to the common iliac bifurcation in both sides (anatomical level 1).
4. Patients with TNM T stage I-IIIB.
5. FIGO stage IIIC1 cervical cancer by positive pelvic sentinel lymph node from surgical staging (either intraoperative assessment (frozen section) or from final histology - patients are not eligible after radical hysterectomy, and FDG-negative common iliac of para-aortic lymph node on PET/CT (performed before or after SLN procedure)
6. Patient eligible for pelvic radiotherapy and cisplatin-based chemotherapy with a curative intent as confirmed by a multidisciplinary board
7. ECOG performance status < 2 i.e. 0 or 1
8. Life expectancy more than 12 months
9. Pretherapeutic imaging FDG-PET/CT images should be available for central review
10. Prior validation of the surgeon's participation in the study by the Quality Assurance Comity
11. Women should be post-menopaused or willing to accept the use of an effective contraceptive regimen during the treatment period. All non-menopaused women should have a negative pregnancy test within 72 hours prior to study entry.
12. Patient is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up
13. Not applicable since protocol revision V4. Patient participating to other clinical trials including immunotherapy strategies or adjuvant chemotherapy is also eligible for the study. Adjuvant treatment must be decided prior to randomization
14. Signed informed consent
15. Patient affiliated to a Social Health Insurance in France (French patients only).

Exclusion Criteria:

1. Unequivocal positive common iliac or para-aortic lymph nodes at pretherapeutic imaging FDG-PET/CT
2. Negative or equivocal pelvic lymph nodes at pretherapeutic imaging FDG-PET/CT
3. Metastatic disease confirmed by FDG-PET/CT
4. Other histologies than adenocarcinoma, squamous cell carcinoma and adenosquamous carcinoma
5. Contraindication for cisplatin-based chemotherapy
6. Women who received any prior treatment for cervical cancer
7. Prior surgery for the cervical cancer, except for cone procedure and pelvic lymph node staging
8. Previous pelvic radiotherapy
9. History of another primary malignancy except for: Malignancy treated with curative intent and with no known active disease after 5 years, adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease, adequately treated carcinoma in situ (any location) without evidence of disease.
10. Any psychological, familial, geographic or social situation, according to the judgment of investigator, potentially preventing the provision of informed consent or compliance to study procedure
11. Patient who has forfeited his/her freedom by administrative or legal award or who is under legal protection (curatorship and guardianship, protection of justice).

Primary Purpose

Treatment

Allocation

Randomized

Interventional Model

Parallel Assignment

Masking

None (Open Label)

Lead Sponsor

Institut Claudius RegaudOTHER

Collaborators

ARCAGY/ GINECO GROUPOTHER

European Network of Gynaecological Oncological Trial Groups (ENGOT)OTHER

Gynecologic Cancer Intergroup (GCIG)OTHER

Grupo Español de Investigación en Cáncer de OvarioOTHER

Multicenter Italian Trials in Ovarian cancer and gynecologic malignanciesUNKNOWN

Belgian Gynaecological Oncology GroupOTHER

Swiss GO Trial GroupNETWORK

Institute of Cancer Research, United KingdomOTHER

The Central and Eastern European Gynecologic Oncology GroupOTHER

Hellenic Cooperative Oncology GroupOTHER

pierre-francois.dupre@chu-brest.fr02 98 22 37 59

yohan.kerbage@chu-lille.fr03 20 44 66 38

tristan.gauthier@chu-limoges.fr05 55 05 61 64

catherine.ferrer@chu-nimes.fr+33 (0) 4 66 68 32 16

bruno.borghese@aphp.fr+33(0) 1 44 41 23 17

enora.laas@curie.fr+33 (0) 1 44 32 46 53

l.ouldamer@chu-tours.fr02 47 47 47 42

• Para Aortic Lymphadenectomy : Always ?

  NCT04392895

  CompletedObservationalUpdated Jul 29, 2020
• Pretherapeutic Paraaortic Lymphadenectomy in Women With Locally Advanced Cervical Cancer Versus Definitive Chemoradiotherapy

  NCT02848716

  WithdrawnInterventionalPhase 3Updated Nov 17, 2021
• Induction Chemotherapy Followed by Standard Therapy in Cervical Cancer With Aortic Lymph Node Spread

  NCT03534713

  RecruitingInterventionalPhase 3Updated Sep 21, 2023
• Para-aortic Lymph Node Metastasis in Resectable Pancreatic Cancer

  NCT06065891

  RecruitingInterventionalNot ApplicableUpdated Oct 4, 2023
• Para-aortic Prophylactic Irradiation for Locally Advanced Cervical Cancer

  NCT04974346

  RecruitingInterventionalPhase 3Updated Jan 25, 2022
• Concurrent Chemoradiotherapy Combined With Sintilimab as Neoadjuvant Therapy for GC Patients With PALM

  NCT06341595

  RecruitingInterventionalPhase 2Updated Apr 2, 2024